SCS Swiss Chemical Society

Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Swiss Chemistry Science Night 2026 – A Celebration of Chemical Research and the 125th Anniversary of the SCS

On September 18, 2026 the sixth Swiss Chemistry Science Night took place at Casino Bern!

More than 110 invited guests including the 2026 award winners followed the invitation and enjoyed the evening to celebrate excellence in chemical research. Dr. Maud Reiter, dsm-firmenich and Prof. Jeremy Luterbacher, EPFL Lausanne, guided through the evening as moderators and presented the speakers and awardees in dialogue with the SCS president, Prof. Christian Bochet, in a competent and highly entertaining manner. Prof. Ed Constable, professor at the University of Basel, and Dr. Marc Cadisch, director of Spiez Laboratory, opened the evening with their welcome messages before no less than 13 winners for 10 prizes as well as 2 honorary members of the Swiss Chemical Society were awarded. The evening also featured the finals of the SCS 125th Anniversary Game Competition. The three finalists presented their games before the guests voted to determine the rankings of the three winners.

The event honored the winners of the 2026 Swiss Chemical Society Awards in front of distinguished leaders from industry and academia as well as representatives from politics and was a celebration of discovery and innovation in the chemical sciences. The gala was very much appreciated by the community and provided a networking platform for industry and academic members.

After five years of service, Prof. Christian Bochet will step down as SCS President at the end of 2026 and was honored by David Spichiger, SCS Executive Director, for his impact and achievements. Next year Dr. Yves Auberson will take over the mandate and will be the host of the 7th Swiss Chemistry Science Night.

Pictures of the evening and the famous after show photo session are available on the SCS Award website on *https://scg.ch/awards*

SCS Anniversary Game Competition 2026: These are the winners!

As part of the 125th anniversary program of the Swiss Chemial Society, we established the SCS 125th Anniversary Game Competition where participants were asked to create their own chemistry game app. The three finalist were invited to the Swiss Chemistry Science Night in Bern on September 18, 2026, to present their games to the audience in a live demo. The audience voted on the winner:

The winners of the game competition
1. Place: Elementle – The daily periodic table game
Created by ***Stefan P. Schmid*** and ***Magdalena Lederbauer***
2. Place: Mystery on the Chemistry Express
Created by ***Yueqing Shen***
3. Place: Periodic Scrabble: Synthesis!
Created by ***Martin Schwill***

Evaluation Criteria
Functionality, creativity, and surprise of the game as well as a compelling presentation scored high points.

Prize Money
The winning teams received CHF 1'000, 750 and 500.
https://scg.ch

Realignment of the SCS Academy Program Starting in 2027

Over the past few years, the SCS Academy has developed a diverse and high-quality continuing education program covering various fields of the chemical and pharmaceutical sciences. Numerous courses have been successfully conducted over the years, offering our members and other professionals the opportunity to deepen their knowledge, learn about new developments, and exchange ideas with colleagues in the field.

However, we have observed a significant decline in demand for our Academy courses. This also applies to newly developed courses and those covering current topics. Despite great dedication in putting together the program and recruiting proven expert speakers, several events could no longer be held due to insufficient registration numbers.

The SCS Board discussed this development in detail at its last meeting and decided to realign the continuing education offerings starting in 2027. In the future, the SCS Academy will focus on a smaller number of established courses that have proven successful in recent years and have consistently generated significant interest.

This realignment marks the end of a long and successful phase for the SCS Academy in its current form. We would therefore like to extend our heartfelt thanks, in particular, to all the speakers who have supported us over the years with their expertise, their time, and their great dedication. Without their willingness to share their knowledge with our community, the diverse Academy program would not have been possible.

Our thanks also go to all participants who attended our courses and contributed to the further development of our continuing education offerings through their interest and feedback.

Even though the range of courses will be smaller in the future, our goal remains to offer our members and the chemical community relevant and high-quality opportunities for professional development and exchange.

We thank you for your understanding and look forward to continuing to offer interesting continuing education programs and events in the future.

Fascinating Connections Between Chemistry, Discovery and Switzerland: a fun quiz to celebrate the SCS anniversary



To celebrate the 125th anniversary of the Swiss Chemical Society (SCS), Dr. Ferdinand Wild has created ten exciting chemistry quizzes.

The individual questions were published on the ChemistryViews website between September 7 and 18, 2026 and are summarized in the article collection via the link above.

From ancient pigments and alchemy to polymers, hydropower and Nobel Prize experiments, there are exciting stories and fascinating facts all connected to Switzerland and chemistry. The 10 topics of the quiz questions are:

- Ancient Blue Pigments
- From Barges to Boats
- Hydropower and History
- Who Invented Epoxy Resins?
- Cheese, Alchemy, and the First Plastics
- A Hidden Link to Switzerland
- The Experiment That Secured a Nobel Prize
- The Hunt for Gold-Makers
- Scientific Excellence and Moral Courage
- Mother's Little Helper

We hope you enjoy the quiz questions and the discussions with your colleagues.

You can access the quiz on the website of ChemistryViews on *https://www.chemistryviews.org/fascinating-connections-between-chemistry-discovery-and-switzerland/*

Ilmac Lausanne 2026 continues to grow and strengthens its role as Western Switzerland's life sciences platform

Ilmac Lausanne 2026 has concluded after two exhibition days with clear growth: 3,952 participants – 18.6% more than in 2024 – attended the event, alongside 213 exhibitors, representing an increase of 7% compared with the previous edition. Exhibition space also grew. More than 70 expert presentations, pitches and discussion formats focused on key future topics including automation, artificial intelligence, Process Analytical Technology and biotech. A fully booked Startup Area, concrete partnership and project enquiries, and the Future of Life Sciences Area held in Lausanne for the first time underline Ilmac's growing importance as a platform for innovation and business in Western Switzerland. The renewed increase in visitor numbers confirms Ilmac Lausanne's growing relevance as a meeting place for companies, researchers, technology providers and professionals from Western Switzerland and beyond.

"Ilmac stands for quality, relevance and targeted networking within the life sciences and chemical industries. It is a carefully curated platform that brings the right industry participants together: exhibitors, content, speakers and visitors are connected with a clear focus on quality, relevance and decision-making authority. Ilmac Lausanne has demonstrated particularly clearly how important this format is for the industry. It brings technology, science and industrial practice together, creating tangible collaborations, projects and business opportunities. The high quality of the discussions and the strong presence of decision-makers confirm this ambition. At the same time, Ilmac Lausanne creates an important bridge to Western Switzerland and complements Ilmac Basel ideally" says Céline Futterknecht, Exhibition Director of Ilmac.

SCS partnered with the SGVC and BioAlps to organize the Ilmac Conference

The first day of the conference focused on Process Analytical Technology (PAT) and explored how data-driven process monitoring, digital models and automation can improve quality, efficiency and sustainability in production processes. The second day was dedicated to biotech, biotools and the Swiss life sciences ecosystem. Together with partners including the Swiss Chemical Society, BioAlps, the Canton of Vaud, Innovaud and the Swiss Biotech Association, the program explored how new technologies can be transferred more rapidly from research and development into practical applications.

International speakers added further perspectives. Professor Brian Freeland of Dublin City University examined the use of Process Analytical Technologies, digital twins and data-driven models to make bioprocesses more efficient and sustainable.

The contributions highlighted a clear message: the future competitiveness of the industry will increasingly depend on how successfully data, automation, biotechnology and industrial implementation are brought together.

https://scg.ch/ilmac/2026 and https://ilmac.ch

IUPAC Calls for Project Proposals and Strategic Areas

The IUPAC Science Board has been reviewing the IUPAC project system and is introducing a number of changes aimed at strengthening the impact, coordination, and strategic direction of IUPAC projects.

A key development is the introduction of Strategic Areas – mid- to long-term areas of focus that will help guide IUPAC projects and signal where the Union intends to concentrate its influence and resources. Strategic Areas will complement, rather than replace, IUPAC's fundamental work in areas such as nomenclature, terminology, chemical data standards, and the Color Books. Two Strategic Areas have already been safeguarded from the outset: Language and Standards of Chemistry and Delivering Green and Sustainable Chemistry.

The Science Board is now inviting the IUPAC community to propose additional Strategic Areas, with new areas scheduled to launch in January 2028. Individuals, task groups, Divisions, and National Adhering Organizations (NAOs) are encouraged to put forward forward-looking themes that connect IUPAC's core strengths with emerging scientific and global challenges. The deadline for Strategic Area proposals is 15 December 2026.

Source: *https://iupac.org*

A Warm Welcome to Our New Members!

Period: 18.08.2026–21.09.2026

Amira Abou-Hamdan, Pully - Ujas Acharya, Echandens - Elias Behling, Basel - Yan Berset, Bossonnens - Alessandro Castrogiovanni, Basel - Jiesheng Du, Zurich - Matthias Eckl, Au ZH - Mosè Fabbri, Geneva - Johanna Feuchter, Cugy VD - Thomas Fischer, Lausanne - Michael Füeg, Olten - Sven Hausammann, Gümli-

gen - Dilay Kepil, Zurich - Emma Labordet, Dübendorf - Dea Morina, Bern - Omar Moya Romero, Lausanne - Luis Andres Perez Perez, Fribourg - Paul Rathke, Zurich - Lukas Rost, Zurich - Saskia Schweiss, Basel - Ghali Sekkat, Basel - Cécile Thomas, Aubonne - Louis Vidal, Bonneville - Margit Winkler, Wädenswil.
Become a member: *https://scg.ch/membership*

HONORS, AWARDS, APPOINTMENTS

Congratulations from the RSC on the occasion of the 125th anniversary and the Swiss Chemistry Science Night 2026

«The Royal Society of Chemistry sends its best wishes to the Swiss Chemical Society on the occasion of its 125th anniversary.

Our two Societies go back a very long way – a partnership of co-operation and mutual respect. And we continue to work together - both as individual chemical societies, coming together, and as members of the European Chemical Society.

Looking through our archives, we found greetings from the Swiss Chemical Society to the Chemical Society of London – the predecessor of the RSC – congratulating the Chem Soc of London on its 100 year anniversary – that was in 1941. So our ties go back, at the very least, 85 years – and no doubt longer.
It's an immense pleasure to send our congratulations on this auspicious occasion. We wish you a wonderful evening.
Professor Robert Mokaya RSC President 2026–2028
Dr Helen Pain, Chief Executive»

Prof. Ed Constable conveyed the RSC's congratulations and greetings to the guests in attendance in his speech at the 6th Swiss Chemistry Science Night, which took place at the Casino in Bern on September 18, 2026.

JOURNAL NEWS

Helvetica, Volume 109, Issue 9, September 2026

Perspective
Musical Chemistry and Spectroscopy: Analogies Bridging Two Worlds in Multiple Dimensions
Ricardo J. Fernández-Terán

Synthetic Procedure
Development of a Continuous-Flow Curtius Rearrangement for the Scalable Preparation of a Protected 3-Aminobicyclo[1.1.1]Pentane-1-carboxylate
Nicola Zanda, Bastien Raison, Pascal Giorgi, Roman Lagoutte, Alec E. Morrison

Research Article
Isostructural Analysis in Proposed Crystallization Mechanisms at the Molecular Level of Methyl 4-bromobenzoate and Methyl 4-iodobenzoate
Patrick Teixeira Campos, Isabella Burchardt Ferreira, Rubia Mara Siqueira da Silva

A Straightforward Transformation of ent-Trachylobanoic Acid Into Functionalized ent-Kauranes Under Conditions of Modified Prevost–Woodward Reaction
Marina Grinco, Olga Morarescu, Alic Barba, Nicon Ungur, Veaceslav Kulcițki

The Potential of N-Benzyl Spiro-Oxindole Hydantoins as Antileishmanial Agents Against *Leishmania infantum*
Maria B. V. Moura, Mayara S. Maia, Gerd B. Rocha, Maria C. Sousa, Anthony J. Burke

Chlorinated Byproducts in Diisocyanates Synthesis From ^{35}Cl Nuclear Quadrupole Resonance
Anna Giorgia Nobile, Shahar Dery, Thomas Maximilian Wurm, Andree Pauschinger, Karsten Seidel, Irene de Wispelaere, Andrei-Nicolae Parvulescu, Christophe Copéret

Flow Synthesis of Muscone-Macrocycles Using the Eschenmoser Rearrangement as a Key Step
Merlin Hauer, Oliver Fifield, Florian Fricke, Alexandra Seeman, Ian R. Baxendale, Johannes Panten, Andreas Kirschning

Molybdenum-95 Nuclear Magnetic Resonance Signatures of Molybdenum–Imido Olefin Metathesis Pre-Catalysts
Jérémy Roudin, Felix J. de Zwart, Christoph J. Kaul, Victor Böttcher, Alexander V. Yakimov, Christophe Copéret

INDUSTRIAL NEWS SWITZERLAND

Source: *www.chemanager-online.com*

Samanta Cimitan to Become CCO of Lonza

August 26, 2026: Samanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President, and a member of the extended Executive Committee, effective January 1, 2027. Lonza has announced the appointment of Samanta Cimitan as Chief Commercial Officer (CCO), Senior Vice President, and member of the Extended Executive Committee. Cimitan will join the Swiss contract development and manufacturing organization (CDMO) no later than January 1, 2027. In this newly created role, she will oversee Strategic Enterprise Account Management, Global Marketing, and Commercial Excellence. She will also have direct commercial responsibility for Lonza's strategic customers and will work with the Commercial Excellence and Global Marketing teams to develop a unified market approach for the company. In line with the One Lonza strategy, the position is intended to help facilitate customer access to Lonza's global end-to-end offering across all three business platforms. Wolfgang Wienand, Chief Executive Officer of Lonza, stated: "The appointment of Samanta Cimitan as Chief Commercial Officer is another important step in building One Lonza and in harnessing the full power of the Lonza Engine for our partners in the pharmaceutical industry. Our goal is clear: Every customer should benefit from the unique breadth of our scientific, technological, and manufacturing expertise so that groundbreaking innovations can be translated into effective therapies for patients worldwide. Samanta Cimitan brings deep CDMO expertise, extensive experience in commercial leadership, and first-hand knowledge of Lonza. She knows how to build trusting partnerships, consistently deliver on commercial goals, and create value throughout the entire development and manufacturing chain. "I am very pleased to welcome Samanta back to Lonza as we continue to sharpen our commercial focus and pursue our goal of making the medicines of tomorrow a reality." Samanta Cimitan has many years of leadership experience in the CDMO industry and has

built a successful career in sales strategy, customer partnerships, and operational execution. She is currently CEO of the Celonic Group, where she has driven the company's evolution into a focused biologics CDMO and strengthened its commercial, operational, regulatory, and innovation capabilities. Prior to joining Celonic, Cimitan worked at Lonza for nearly 13 years. There, she held various leadership positions in sales and strategy, including the role of Vice President of Group Operations Strategy. In this role, she developed and led transformation programs in sales, research & development, and manufacturing.

Samsung Biologics Launches CHF 1.46 Billion Tender Offer for PolyPeptide

September 1, 2026: Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs. Samsung Biologics, a contract development and manufacturing organization (CDMO), through its direct Swiss subsidiary, Samsung Peptide, has published the tender offer prospectus for all publicly held registered shares of PolyPeptide. PolyPeptide shareholders will receive CHF 44.31 net in cash for each PolyPeptide share, representing an implied aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium compared with the unaffected price of PolyPeptide's shares on the SIX Swiss Exchange ("SIX") as of April 10, 2026, which was the last trading day prior to the publication of the first media speculation regarding a potential acquisition of PolyPeptide. The offer price represents a premium of 11.6% compared with the volume-weighted average share price over the last 60 trading days prior to the pre-announcement on July 20, 2026. The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that PolyPeptide's shareholders accept the offer. The recommendation is further supported by an independent fairness opinion from IFBC AG.

Draupnir Holding, PolyPeptide's largest individual shareholder, who holds approximately 55.65% of the total PolyPeptide shares outstanding, has undertaken to tender all of its shares into the offer. The main offer period commences on Sept. 15, 2026 and is expected to end on Oct. 12, 2026. The offer is subject to a minimum acceptance threshold of 66⅔% on a fully diluted share count basis (excluding treasury shares), applicable regulatory approvals, and other customary conditions described in the Offer Prospectus. Following the settlement of the offer, Samsung Peptide intends to pursue a squeeze-out of any remaining minority shareholders and to delist PolyPeptide's shares from the SIX.

Lonza Announces Addition of Commercial Spray-Drying Facility at Bend Site

September 10, 2026: The investment will reinforce the Bend site as a center of excellence for particle engineering and bioavailability enhancement and create a global manufacturing hub for commercial spray-drying. Lonza, a contract development and manufacturing organization (CDMO), announced today plans to further strengthen its significant US presence by constructing a large-scale commercial spray-drying facility in Bend, Oregon. The investment will establish Lonza as the leading CDMO provider of commercial-scale spray-drying PSD-4 capacity in the US. Lonza will offer a full range of spray-dried dispersion (SDD) capacity to support customers across both clinical and commercial programs. Through its integrated end-to-end offering, Lonza will support the development and manufacturing of small molecules and other modalities, including biologics and mRNA. SDD technologies are increasingly relevant in modern drug development, as the industry addresses the growing complexity of molecules and their related bioavailability challenges. The demand for SDD CDMO services has grown alongside the increasing scientific complexity of pharmaceutical pipelines, driven by the increasing prevalence of poorly soluble drug substances. Today, a significant share of molecules in the clinical pipeline requires bioavailability enhancement. The Bend expansion is intended to meet this growing market demand, with a particular focus on the US demand, enabling Lonza to provide customers with an additional option to access a complete and integrated end-to-end development and manufacturing solution for SDDs. Wolfgang Wienand, Chief Executive Officer, Lonza, said: "The investment in the Bend site reflects our conviction that the United States will remain a leading source of pharmaceutical innovation and a key market for Lonza. It also delivers on our One Lonza strategy, powered by the Lonza Engine, to invest where we can create the greatest value for our customers and, ultimately, for patients. By significantly expanding our commercial-scale spray-drying capabilities, we strengthen a technology that can fundamentally improve the delivery and bioavailability of medicines. With this, our world-class particle engineering team in Bend will be even better able to support our customers in turning their breakthrough innovations into viable products and to manufacture the medicines of tomorrow." Christian Seufert, Head of Advanced Synthesis, Lonza, added: "The growing number of complex drug molecules is increasing demand for advanced particle engineering technologies. With decades of expertise in spray-drying, our Bend team helps customers address formulation challenges and progress their programs efficiently. This investment expands the capacity and capabilities needed to support customers from development through commercialization." The new facility will be equipped with two state-of-the-art PSD-4 spray-drying units, allowing for future capacity expansions as demand continues to grow. Additional upgrades to the Bend site include supporting infrastructure for solvent handling and storage. The project also integrates energy-efficient utility and process systems and enhanced emission control technologies to reduce overall facility energy demand. The new facility, expected to be completed in 2029, will be delivered through a significant capital investment and will initially create more than 80 new jobs, highlighting Lonza's commitment to expanding its manufacturing footprint in the US. The expansion enhances proximity to key customers and supports more resilient, regionalized supply chains for critical therapies.

Prange Group Sells Remaining Shares in Adragos Pharma

September 18, 2026: German contract development and manufacturing organization (CDMO) Prange has sold all remaining shares in Adragos Pharma to FSN Capital. In 2021, FSN Capital partnered with Prange Group, Plettenberg, Germany, to accelerate the development and growth of Adragos Pharma. Over the past five years, Adragos Pharma has expanded its international network and capabilities across Europe and Japan. Now, Prange Group has sold all of its remaining shares in Munich-based Adragos Pharma. Following the transaction, FSN Capital VI together with management remains the sole shareholders in Adragos Pharma. The parties have agreed not to disclose the financial details of the transaction. Kostas Rengis, CEO of Adragos Pharma, commented: "We thank Prange Group for its contribution to Adragos Pharma over the past years. With FSN Capital's continued support, we are now focused to further strengthen our operations, expand our development services, enhance our international network and continue to build Adragos into a leading international CDMO supporting our customers from clinical development and trials to commercial manufacturing." Adragos Pharma operates an integrated CDMO network comprising its R&D center in Athens and manufacturing sites in France (Maisons-Alfort and Livron), Switzerland (Jura), Germany (Leipzig) and Japan (Kawagoe). With the completion of the transaction, Prange Pharma,

the pharmaceutical holding and operating company of the family-run Prange Group, will place a stronger strategic focus on expanding its own operational CDMO platforms in human and animal health. Sebastian Heckerodt, CEO of Prange Pharma, said: "We look back on the joint development of Adragos Pharma with great appreciation. Now we want to further expand our CDMO activities with Halden Pharma and Aprilia Animal Health and develop strong partnerships with our customers and teams in the long term."

Nine Major European Pharma Companies Warn of Investment Decline in Joint Open Letter

September 25, 2026: Chairs of nine of Europe's biggest drugmakers – AstraZeneca, Boehringer Ingelheim, Chiesi, Ipsen, GSK, Novo Nordisk, Novartis, Roche and Sanofi – issued a joint open letter warning that Europe is falling behind the US and China in pharmaceutical investment and research. The letter cites over $600 billion in pharma investment announced in the US and China in the past two years, and notes Europe's share of global drug R&D has dropped from 43% in 1990 to just 31% today. The executives are urging EU and national leaders to modernize health policy and treat innovative medicines as strategic infrastructure, warning that without reform, Europe's "comeback" opportunity could slip away.

Open Letter:

"We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and beyond. Our duty is to safeguard our companies' future so that we can continue to discover and develop life-changing medicines for patients.

The pharmaceutical sector is one of our continent's great post-war achievements. Built on investment in science, world-class universities, and the determination to discover medicines that change lives. Europe gave the world vaccines, pioneered treatments for heart disease, and laid the foundation for today's cancer treatments – transforming public health.

Europe's choice to incentivise discovery built one of our most productive and research-intensive sectors, supporting millions of highly skilled jobs, and generating an EU trade surplus of over €220 billion. The uptake of innovative medicines in Europe returns almost sixfold to the economy through lower hospitalisation costs and healthier working lives. Our sector powers a vast ecosystem spanning discovery, development and manufacturing, while strengthening health systems to manage rising burdens of disease and ageing populations.

But this hard-won inheritance is at risk. In our boardrooms, we see Europe losing ground to global competition. Over $600 billion in pharmaceutical investment has been announced in the US and China in the last two years alone. European governments must create conditions that attract investment in next-generation medicines before it's too late.

Europe's alarm bells are ringing. As Mario Draghi warned, without urgent action, strategic sectors like pharmaceuticals face a 'slow agony' of decline. In 1990, Europe accounted for 43% of global pharmaceutical R&D. Today, it is 31% and falling. Europe's share of commercial clinical trials, which provide vital revenue for public hospitals and improve patient outcomes, has halved in a decade to 9%. China has overtaken Europe in clinical trials, pharmaceutical patents, and the development of new medicines.

For patients, the consequences are clear: around 40% of newly approved therapies never reach European patients. Among those that do, patients wait nearly 600 days for treatment. Cancer survival in Europe trails the US1. Too many patients are diagnosed late or treated with medicines that fall short of the standard recommended by medical guidelines.

This is the result of decades in which Europe treated medicines as a cost to suppress rather than one of the best investments a government can make. Outdated systems constrain the use of innovative medicines, arbitrarily cap budgets, and fail to adjust spending for inflation despite rising patient need. Government policies send a powerful signal about how innovation is valued and the priority placed on ensuring that patients can access it.

The message to innovators has been stark: Europe does not value what you do.

The decisions we take have consequences today and for years to come. A single innovative medicine takes more than a decade and around €3 billion of at-risk investment before reaching a patient, with only one or two medicines emerging from every 10,000 candidates synthesised in laboratories. Few sectors face comparable risk over such long horizons. That commitment requires a market that rewards it.

It is becoming more urgent to change course. European leaders must recognise the danger. The EU can play an enabling role by accelerating clinical trials, protecting intellectual property, and adopting sensible digital policies. Crucially, the EU could also provide fiscal flexibility to Member States investing in health and innovative medicines, recognising these returns take time to materialise.

But EU action alone is not enough. The decisive levers lie with national governments: how much to invest in health budgets, how quickly new medicines are assessed and funded, and how to modernise healthcare to better prevent, detect and treat disease.

We ask national leaders to work with us to reverse Europe's declining competitiveness, unleash a new era of medical discovery, and secure health sovereignty. We recognise the fiscal pressures many face. But just like defence or energy, modern medicines should be treated as vital infrastructure and not be left to others to provide.

Opportunities are on Europe's doorstep if governments rebalance decades of underinvestment in innovative medicines and modernise value frameworks to reflect the total value of what these treatments bring to patients, health systems and the economy. In clinical trials alone, Europe could unlock €53 billion and 82,000 jobs by closing the gap with China and the US.

Europe's story does not have to be one of decline and dependency; it can be one of renewal and resilience. That choice belongs to national leaders and all of us as citizens. If we fail to act with ambition, our future will be built elsewhere. But if we choose to invest in health and medicines as strategic assets, Europe will not merely catch up – it can set the pace of global innovation once again and enable Europeans to live longer, healthier lives."

- Michel Demaré, Chair of the Board, AstraZeneca
- Hubertus von Baumbach, Chairman of the Shareholders' Committee, Boehringer Ingelheim
- Maria Paola Chiesi, Chair of the Board, Chiesi Group
- Marc de Garidel, Chairman of the Board, Ipsen
- Jonathan Symonds CBE, Chair of the Board, GSK
- Lars Rebien Sørensen, Chair of the Board of Directors, Novo Nordisk
- Giovanni Caforio, Board Chair, Novartis
- Severin Schwan, Chairman of the Board, Roche
- Frédéric Oudéa, Chairman of the Board, Sanofi

Source: CHEManager | CHEManager International
Wiley-VCH GmbH, 69469 Weinheim, GERMANY,
E-Mail: *chemanager@wiley.com*